Expert Consensus Statement from the American Society of Echocardiography on Hypersensitivity Reactions to Ultrasound Enhancing Agents in Patients with Allergy to Polyethylene Glycol

Affiliations

¹ Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon. Electronic address: lindnerj@ohsu.edu.
² Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon.
³ Saint Luke's Mid America Heart Institute, Kansas City, Missouri.
⁴ Division of Immunology and Allergy, Oregon Health & Science University, Portland, Oregon.
⁵ Maritime Heart Center, Dalhousie University, Halifax, Nova Scotia, Canada.
⁶ Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
⁷ Department of Pharmacy Practice, Oregon State University, Corvallis, Oregon.
⁸ National Heart and Lung Institute, Imperial College, London, United Kingdom.

Jonathan R Lindner et al. J Am Soc Echocardiogr. 2021 Jul.

. 2021 Jul;34(7):707-708.

doi: 10.1016/j.echo.2021.05.002. Epub 2021 May 7.

¹ Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon. Electronic address: lindnerj@ohsu.edu.
² Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon.
³ Saint Luke's Mid America Heart Institute, Kansas City, Missouri.
⁴ Division of Immunology and Allergy, Oregon Health & Science University, Portland, Oregon.
⁵ Maritime Heart Center, Dalhousie University, Halifax, Nova Scotia, Canada.
⁶ Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
⁷ Department of Pharmacy Practice, Oregon State University, Corvallis, Oregon.
⁸ National Heart and Lung Institute, Imperial College, London, United Kingdom.

No abstract available

Keywords: MedWatch; PEG; Ultrasound enhancing agents.

Comment in

We Need to Inform COVID-19 Vaccinating Clinics Concerning Polyethylene Glycol Allergy.
Gelfman DM. Gelfman DM. J Am Soc Echocardiogr. 2021 Nov;34(11):1229-1230. doi: 10.1016/j.echo.2021.08.010. Epub 2021 Aug 23. J Am Soc Echocardiogr. 2021. PMID: 34438025 Free PMC article. No abstract available.
Ultrasound-Enhancing Agents and Associated Adverse Reactions: A Potential Connection to the COVID-19 Vaccines?
Soni M, McGovern M, Jacob R, Weiss R, Adusumalli S, Litwin S, Jagasia D, Scherrer-Crosbie M. Soni M, et al. J Am Soc Echocardiogr. 2022 Feb;35(2):241-242. doi: 10.1016/j.echo.2021.09.014. Epub 2021 Oct 7. J Am Soc Echocardiogr. 2022. PMID: 34627975 Free PMC article. No abstract available.

1. Porter TR, Mulvagh SL, Abdelmoneim SS, Becher H, Belcik JT, Bierig M, et al. Clinical Applications of Ultrasonic Enhancing Agents in Echocardiography: 2018 American Society of Echocardiography Guidelines Update. J Am Soc Echocardiogr. 2018;31:241–274. - PubMed
1. Lindner JR, Coggins MP, Kaul S, Klibanov AL, Brandenburger GH and Ley K. Microbubble persistence in the microcirculation during ischemia/reperfusion and inflammation is caused by integrin- and complement-mediated adherence to activated leukocytes. Circulation. 2000;101:668–75. - PubMed
1. Wei K, Mulvagh SL, Carson L, Davidoff R, Gabriel R, Grimm RA, et al. The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. J Am Soc Echocardiogr. 2008;21:1202–6. - PubMed
1. Muskula PR and Main ML. Safety With Echocardiographic Contrast Agents. Circ Cardiovasc Imaging. 2017;10. - PubMed
1. Szebeni J Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005;216:106–21. - PubMed